Another study reported effective treatment with trametinib for the Erdheim–Chester disease (ECD) and Rosai–Dorfman disease (RDD) subgroups of human histiocytic disorders with mutations in BRAF or other MAPK pathway-associated genes [11]. Here, BRAF is linked to sinus histiocytosis with massive lymphadenopathy.